Bradanicline

DB06090InvestigationalSmall molecule

Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7). Bradanicline belongs to a new class of drugs for the treatment...

Mechanism: Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7). The α7 NNR is associated with a variety of biological functions. In particular, the α7 NNR has been shown in animal studies to be an essential regulator of both inflammation arising from injury or infection and cognitive functions. α7 NNR plays a role in protecting neuronal cells from deterioration and death, a process known as neuroprotection.
Curator reviewed
Primary indication: Investigated for use/treatment in neurologic disorders.Curator reviewed
Formula / weight: C₂₂H₂₃N₃O₂ · 361.445 g/mol (avg)
Code names: TC-5619

Resolves to

Compound

UNIIUM3821998KCAS639489-84-2ChEMBLCHEMBL1258006PubChem25147644

Structure

InChIKeyOXKRFEWMSWPKKV-GHTZIAJQSA-NSMILES[H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2

Targets

P36544CHRNA7

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bradanicline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account